Marc Bosiers (St. Blasius Hospital, Dendermonde, Belgium) will give an update at LINC today on the results of the REFLOW1 study, which investigated the efficacy of the LEGFLOW® drug-coated balloon (DCB) in TASC C and D femoropopliteal lesions.
Professor Dr Qizhuang Jin (Peking University First Hospital Nephrology Department, China) spoke to LINC Today about the recently published results of the first randomised controlled trial (RCT) comparing the APERTO® drug-coated balloon (DCB) with high pressure angioplasty balloon in the treatment of arteriovenous fistulae (AVF) lesions.
In a Q&A with LINC Today, Michael Lichtenberg, angiologist at Klinikum Hochsauerland GmbH, Arnsberg, Germany, discussed the APERTO® OTW (over-the-wire) drug coated balloon (DCB) currently being trialled in haemodialysis patients with central venous stenosis (CVS) in a bid to improve patency of arteriovenous fistulas (AVFs).
Cardionovum invites you to participate in on demand interviwes:
XLIMIT Trial RCT, with Dr. Luca Testa from Italy. Goal: to assess angiographic and clinical performance of the Xlimus Biodegradable Polymer Sirolumus-eluting stent versus a gold standard like Synergy Biodegradable Polymer Everolimus Stent in patients treated with percutaneous coronary angioplasty.
Hyper Registry with Dr. Alfonso Ileasi from Italy. Goal: Asses the clinical results after a Hybrid Approach in diffuse CAD lesions longer tan 28mm combinig Restore DCB and New generation DES.